All dose levels of Radspherin® were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study.

Radspherin® is currently being evaluated in two ongoing Phase 1 trials for the treatment of peritoneal carcinomatosis from ovarian cancer and colorectal cancer

Oncoinvent would like to extend an invitation to a presentation of the Q1 2022 results. The presentation will be held on Wednesday 1. June 2022 at 08:30 AM in the offices of the company at Gullhaugsveien 7, Oslo, 3rd Floor. To attend, please register with kvam@oncoinvent.com. Oncoinvent ønsker med dette å invitere til presentasjon av … Read more

CEO, Jan A. Alfheim, will present Oncoinvent at the DNB Small & Medium Enterprises Conference and host 1-on-1 meetings with investors on April 7, 2022

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming virtual investor conferences:

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.